← All trials
NCT04948164
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2018
- Primary completion
- Dec 1, 2021
- Completion date
- Dec 1, 2021
- First posted
- Jul 1, 2021
- Last posted
- Jul 7, 2021
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Peking UniversityLead sponsor
- Peking UniversityOverall official - principal investigator
- Guangzhou Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Central South UniversityCollaborator
- Jilin UniversityCollaborator
- Kunming Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Sichuan UniversityCollaborator
- Capital Medical UniversityCollaborator
- Qingdao UniversityCollaborator
- Nanjing Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.